Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Breakthrough Breast Cancer's Comment On New Targeted Antibody Therapy For Advanced Her2-Positive Breast Cancer
Dr Alexis Willett, Head of Policy & Involvement at Breakthrough Breast Cancer, says:
generic viagra online
Md. County's Model Health Program For The Uninsured Faces Some Obstacles
One Maryland county"s tiny new health care programs for the uninsured could be a model for providing care nationwide, National Public Radio says in an ongoing series. The program is cheap, effective and heavy on preventive care, Howard County"s health commissioner, Dr. Peter Beilenson says. The program, called Healthy Howard, provides care for families of four earning up to $66,000 a year, and patients are required to pay $50 to $85 a month. But some of the enrollees are running into trouble.
News of the day
American Pharmacists Association Seeks Nominations For Practitioner Awards And Honors
The American Pharmacists Association (APhA), the national professional society of pharmacists, announces that nominations are now being accepted for the Association"s practitioner awards and honors. Presentation of these awards is scheduled for the APhA Annual Meeting and Exposition in Washington, DC, March 12-15, 2010. Nominations must be received at APhA headquarters by September 15, 2009. APhA"s awards recognition program is American pharmacy"s most comprehensive recognition program.
Medical Devices

Ablynx Announces A Novel Preclinical Development Candidate Targeting IL6R

Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced that it has advanced ALX-0061, a new Nanobody®-based therapeutic programme, into preclinical development for the treatment of autoimmune and inflammatory diseases. ALX-0061 is a selective, low molecular weight biologic, binding to the IL6 receptor (IL6R). It has a very high potency and demonstrated a favourable PD, PK and safety profile in preclinical testing compared with the benchmark molecule. ALX-0061 has no Fc-mediated effector function which may translate into an improved safety profile. It also avoids cross-linking IL6R due to its monovalent binding to the target. The low molecular weight and desirable biophysical properties of this Nanobody® open up opportunities for alternative routes of administration and superior tissue penetration in the clinical setting. The Nanobody® can be manufactured at a relatively low cost in a microbial system. "We are delighted to strengthen our product portfolio by advancing another novel Nanobody®, discovered using our proprietary Nanobody® platform, into preclinical development. It is well positioned to translate into a superior treatment for rheumatoid arthritis and other autoimmune diseases. There are already three Nanobodies® in clinical development, with our lead programme, ALX-0081, a novel anti-thrombotic, on track to start Phase II in the next few months", commented Dr. Edwin Moses, Chief Executive Officer and Chairman of Ablynx. About ALX-0061 (IL6R) ALX-0061 is a Nanobody® binding to the interleukin-6 receptor (IL6R). It has the potential to differentiate through its high potency, high stability and low molecule weight of only 26kD which should translate into superior tissue penetration, attractive PK/PD and superior safety and efficacy profile compared with a benchmark monoclonal antibody. The involvement of the IL6 pathway in a variety of diseases indicates that multiple indications can be pursued with large market potential including rheumatoid arthritis (RA), Crohn"s disease, Castleman"s disease, multiple myeloma and systemic lupus erythematosus (SLE). College Hill Life Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009